• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Interim Report 31st October 2022

by admin | Oct 31, 2022 | Financial Info

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Preliminary Results for the year ended 30 April 2022

by admin | Oct 28, 2022 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

EuroMAbNet 6th Antibody Validation Workshop and 12th Meeting, Hamburg, 22-24 September 2022

by admin | Oct 28, 2022 | Antibodies, Avidimab, Glymab

EuroMAbNet 6th Antibody Validation Workshop and 12th Meeting, Hamburg, 22-24 September 2022 Unlocking the unique potential of AvidiMAb® in fighting cancer Bubacarr G Kaira, Foram Dave, Elena Dubinina, Omar Mohammed, Bryony Heath, Poonam Vaghela, Ruhul Choudhury, Tina...

Scancell signs Commercial License Agreement with Genmab

by admin | Oct 25, 2022 | GlyMab, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell Change of Registered Office

by admin | Sep 6, 2022 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy